Risk-guided therapy: A first step to personalized medicine

European Journal of Preventive Cardiology

Volumn 19, Issue , 2012, Pages 5-6

  Zannad, Faiez ^a   Koenig, Wolfgang ^b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CARDIOVASCULAR DISEASE; DECISION SUPPORT SYSTEM; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; PERSONALIZED MEDICINE; PREVENTIVE HEALTH SERVICE; RISK ASSESSMENT; RISK FACTOR;

ALGORITHMS; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS;

EID: 84871680200     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487312448991     Document Type: Article

References (3)

1. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769–1818.
2. Fifth Joint European Societies Taskforce. Update to the European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur Heart J 2012; doi: 10.1093/eurheartj/ehs092. Published online 3 May 2012.
3. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.